The overall aim of this application is to better understand the mechanism(s) that lead to diabetes. Of the various common genetic variants associated with type 2 diabetes that in TCF7L2, has the strongest effect on disease predisposition and might provide insight into various diverse mechanisms that drive the progression of prediabetes to diabetes. The product of TCF7L2 is an important constituent of the wnt-signaling cascade that was originally shown to regulate proglucagon gene expression. However, it is apparent that TCF7L2 regulates multiple genes regulating metabolic processes, all of which may be important in the pathogenesis of diabetes. Beta-cell function has been quantified by the Disposition Index (DI) which expresses insulin secretion as a function of insulin action. However, the relationship between these 2 parameters has been assumed to be uniform across various states of glucose tolerance, and indeed different states of beta-cell reserve. Direct measurement of the secretory response in response to an acute decrease in insulin action validate or improve DI as a characterization of beta-cell function and the effect of diabetes-associated variation in TCF7L2 on this measurement. Moreover, incretin hormones (regulated by TCF7L2 have been suggested to be part of the compensatory response to acute decreases in insulin action. Hepatic insulin action is impaired early in the pathogenesis of prediabetes and is characterized by impaired suppression of gluconeogenesis. The contribution of diabetes-associated variation in TCF7L2 to these processes is unknown. Finally, insulin secretion and insulin action decline in parallel across the spectrum of prediabetes. The mechanism(s) underlying this observation are unknown. One potential explanation, supported by animal experiments, is that decreased interdigestive insulin pulsatility leads to decreased hepatic insulin action. The processes regulating the amplitude and frequency of insulin secretion are complex and have been shown to be abnormal in many states associated with increased predisposition to diabetes. A direct effect of diabetes-associated variation in TCF7L2 on insulin pulsatility and amplitude of secretion is unknown. The experimental design will also allow direct correlation of interdigestive insulin secretion with hepatic insulin action in humans. The proposed experiments will directly address how TCF7L2 alters glucose homeostasis and provide insights into the pathogenesis of prediabetes and progression to diabetes.

Public Health Relevance

Genome-wide association studies have identified multiple common genetic variants that predisposed to type 2 diabetes. Of these genetic variation in TCF7L2 has the strongest effect on diabetes risk. However, its direct effects on glucose metabolism and on progression to diabetes are poorly understood. Diabetes-associated variation in this locus provides an opportunity to improve our understanding of the processes driving the conversion of prediabetes to diabetes, refine clinical measurements of beta-cell function and improve our ability to target prevention strategies to predisposed individuals.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK078646-07
Application #
8471691
Study Section
Clinical and Integrative Diabetes and Obesity Study Section (CIDO)
Program Officer
Laughlin, Maren R
Project Start
2007-08-01
Project End
2017-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
7
Fiscal Year
2013
Total Cost
$484,280
Indirect Cost
$156,266
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Vella, Adrian; Jensen, Michael D; Nair, K Sreekumaran (2016) Eulogy for the Metabolic Clinical Investigator? Diabetes 65:2821-3
Varghese, Ron T; Viegas, Ivan; Barosa, Cristina et al. (2016) Diabetes-Associated Variation in TCF7L2 Is Not Associated With Hepatic or Extrahepatic Insulin Resistance. Diabetes 65:887-92
Shah, Meera; Varghese, Ron T; Miles, John M et al. (2016) TCF7L2 Genotype and α-Cell Function in Humans Without Diabetes. Diabetes 65:371-80
Dalla Man, Chiara; Micheletto, Francesco; Sathananthan, Matheni et al. (2016) Model-Based Quantification of Glucagon-Like Peptide-1-Induced Potentiation of Insulin Secretion in Response to a Mixed Meal Challenge. Diabetes Technol Ther 18:39-46
Thompson, Scott M; Vella, Adrian; Thompson, Geoffrey B et al. (2015) Selective Arterial Calcium Stimulation With Hepatic Venous Sampling Differentiates Insulinoma From Nesidioblastosis. J Clin Endocrinol Metab 100:4189-97
Nguyen, Kim T; Billington, Charles J; Vella, Adrian et al. (2015) Preserved Insulin Secretory Capacity and Weight Loss Are the Predominant Predictors of Glycemic Control in Patients With Type 2 Diabetes Randomized to Roux-en-Y Gastric Bypass. Diabetes 64:3104-10
Javed, Asma; Vella, Adrian; Balagopal, P Babu et al. (2015) Cholecalciferol supplementation does not influence β-cell function and insulin action in obese adolescents: a prospective double-blind randomized trial. J Nutr 145:284-90
Vella, Adrian; Cobelli, Claudio (2015) Defective Glucagon-Like Peptide 1 Secretion in Prediabetes and Type 2 Diabetes Is Influenced by Weight and Sex. Chicken, Egg, or None of the Above? Diabetes 64:2324-5
Piccinini, Francesca; Dalla Man, Chiara; Vella, Adrian et al. (2015) A Model for the Estimation of Hepatic Insulin Extraction After a Meal. IEEE Trans Biomed Eng :
Matveyenko, Aleksey; Vella, Adrian (2015) Regenerative medicine in diabetes. Mayo Clin Proc 90:546-54

Showing the most recent 10 out of 49 publications